Journal
CANCER RESEARCH
Volume 68, Issue 21, Pages 8928-8937Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-1145
Keywords
-
Categories
Funding
- Mutua Madrilena Medical Research Foundation (Spain)
- Departament d'Universitats
- Recerca i Societat de la Informacio from Generalitat de Catalunya [2005 SGR 00727]
- European Union [18700]
- Instituto de Salad Carlos III of the Ministerio de Sanidad y Consumo, Government of Spain
Ask authors/readers for more resources
Genetic bioselection of a mutagenized Ad5wt stock in human tumor xenografts led us to isolate AdT1, a mutant displaying a large-plaque phenotype in vitro and an enhanced systemic antitumor activity in vivo. AdT1 phenotype correlates with an increased progeny release without affecting total viral yield in different human tumors and cancer-associated fibroblasts. An approach combining hybrid Ad5/AdT1 recombinants and sequencing identified a truncating insertion in the endoplasmic reticulum retention domain of the E3/19K protein (445A mutation) which relocates the protein to the plasma membrane and is responsible for AdT1's enhanced release. E3/19K-445A phenotype does not correlate with the protein's ability to interact with MHC-1 or induce apoptosis. Intracellular calcium measurement revealed that the 445A mutation induces extracellular Ca2+ influx, deregulating intracellular Ca2+ homeostasis and inducing membrane permeabilization, a viroporin-like function. E3/19K-445A mutants also display enhanced antitumoral activity when injected both intratumorally and systemically in different models in vivo. Our results indicate that the inclusion of mutation 445A in tumor-selective adenoviruses would be a very powerful tool to enhance their antitumor efficacy. [Cancer Res 2008;68(21):8928-37]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available